Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 Point-Of-Care Rapid Antigen Test Kits

09/23/2021 | 03:00am EDT

Celltrion announced that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrust COVID-19 Ag Rapid Test. Celltrion USA will make deliveries to approximately 25,000 U.S. CONUS locations to support military bases, long-term care facilities, community testing sites, critical infrastructure, and other designated places on a weekly basis. The DLA estimates its order volume to be as much as $626 million considering the change in demand by the COVID-19 community transmission rate in the U.S. Celltrion believes that this procurement contract underscores Celltrion's quality, production and supply capabilities as the deal has been awarded after the Department of Defense’s rigorous verification. Celltrion has already proven the quality and safety of DiaTrust earlier this year as the product obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on April 16. Celltrion’s supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea. In addition, Celltrion USA emphasized the firm’s drug distribution performance in the US market for the last three years to demonstrate its ability to perform timely deliveries to 25,000 designated places in the U.S., at a competitive price. Unlike other COVID-19 Antigen Rapid Test kits, DiaTrust is a product that applied two antibodies binding COVID-19 virus to both N-protein and S-protein, respectively, resulting in improved sensitivity of 93.3% and specificity of 99.0%. Also, the infection can be diagnosed within only 15 minutes. The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.


© S&P Capital IQ 2021
All news about CELLTRION, INC.
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/06U.S. to invest another $1 bln in rapid COVID-19 tests
RE
09/23Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 P..
CI
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/20180 LIFE SCIENCES : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trial..
MT
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
08/13CELLTRION : Brazil Approves Celltrion's COVID-19 Treatment for Emergency Use
MT
08/06MARKET CHATTER : Celltrion, TriLink BioTechnologies Enter Deal to Develop mRNA Vaccine Pla..
MT
08/02MARKET CHATTER : Celltrion Healthcare Secures Orders for Anticancer Biosimilars from Brazi..
MT
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulized Form of ..
CI
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2021 1 945 B 1,65 B 1,65 B
Net income 2021 600 B 0,51 B 0,51 B
Net cash 2021 241 B 0,20 B 0,20 B
P/E ratio 2021 49,4x
Yield 2021 0,01%
Capitalization 29 986 B 25 455 M 25 458 M
EV / Sales 2021 15,3x
EV / Sales 2022 12,3x
Nbr of Employees 2 034
Free-Float 76,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 219 500,00 KRW
Average target price 307 785,71 KRW
Spread / Average Target 40,2%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-38.86%25 455
MODERNA, INC.212.57%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-2.12%31 638
ALNYLAM PHARMACEUTICALS, INC.52.81%24 284